Edit |   |
---|---|
Antigenic Specificity | IL23A, Human (Mirikizumab biosimilar) |
Clone | Mirikizumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG4 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | n/a |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human IL23A Recombinant Antibody (Mirikizumab). Mirikizumab (INN, development code LY3074828) is a human monoclonal antibody designed for the treatment of psoriasis. This drug was developed by Eli Lilly and Co. As of 2018, mirikizumab is undergoing Phase III trials. |
Immunogen | n/a |
Other Names | Anti-IL23A Recombinant Antibody, Research Grade Mirikizumab, Anti-Human IL23A Recombinant Antibody(Mirikizumab), LY-3074828, Antibody Drug Analogues, Monoclonal Antibody, YR1481, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 1884201-71-1 |
Catalog # | YR1481 |
Price | please inquire |
Order / More Info | IL23A, Human (Mirikizumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |